From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy Ann Intern Med. 1998;128(3):165-175. doi:10.7326/0003-4819-128-3-199802010-00001 Figure Legend: Flow chart showing patients who were entered into the primary diet failure group.After a 3-month run-in period of diet therapy alone, 560 of 4075 patients with newly diagnosed type 2 diabetes continued to have fasting plasma glucose levels greater than 15.0 mmol/L or hyperglycemic symptoms and were randomly assigned to different intensive therapies. Data from 458 patients allocated to insulin, sulfonylurea, or metformin therapy at 6 years are reported. The numbers of nonobese/obese patients in each group are shown. After the initial 3 months of diet therapy, 764 patients had fasting plasma glucose levels less than 6.0 mmol/L and 2769 patients had fasting plasma glucose levels of 6.0 to 15.0 mmol/L; the latter patients were allocated to diet alone or to insulin, sulfonylurea, or metformin therapy in the main randomization group. Date of download: 10/20/2017 Copyright © American College of Physicians. All rights reserved.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy Ann Intern Med. 1998;128(3):165-175. doi:10.7326/0003-4819-128-3-199802010-00001 Figure Legend: Median fasting plasma glucose levels (top) and hemoglobin A1c concentrations (bottom) over 6 years in patients in the primary diet failure group who were allocated to insulin (squares), sulfonylurea (triangles), or metformin (Xs).1cThe left panels show data from nonobese patients; the right panels show data from obese patients. The horizontal dashed lines indicate plasma glucose levels of 6.0 and 7.8 mmol/L and hemoglobin A concentrations of 0.062 (the upper 97.5th percentile of the normal range in our laboratory). Date of download: 10/20/2017 Copyright © American College of Physicians. All rights reserved.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy Ann Intern Med. 1998;128(3):165-175. doi:10.7326/0003-4819-128-3-199802010-00001 Figure Legend: Percentage of patients in the primary diet failure group who required additional therapy at 6 years, according to allocated therapy.The number of patients included in each section is given inside the bar for each therapy group. The left panel shows data from nonobese patients; the right panel shows data from obese patients. C = chlorpropamide; G = glyburide; I = ultralente insulin; M = metformin; OHA = oral hypoglycemic agents. Date of download: 10/20/2017 Copyright © American College of Physicians. All rights reserved.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy Ann Intern Med. 1998;128(3):165-175. doi:10.7326/0003-4819-128-3-199802010-00001 Figure Legend: Kaplan-Meier estimates of the survivor functions for the proportion of patients in the primary diet failure group who required additional therapy.Top.Bottom.2arrow2dashed line2dotted lineEstimated survivor functions for patients classified according to tertiles of age younger than 46 years, 46 to 57 years, and older than 57 years. Estimated survivor functions for patients classified by obesity according to tertiles of body mass index less than 23 kg/m ( ), 23 to 27 kg/m ( ), and greater than 27 kg/m ( ). The lighter dashed line indicates the estimated survivor function for all patients in the main randomization group (MR) who received intensive treatment. Numbers between the graphs are the numbers of patients at risk at annual intervals in the primary diet failure (PDF) and main randomization groups. Date of download: 10/20/2017 Copyright © American College of Physicians. All rights reserved.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy Ann Intern Med. 1998;128(3):165-175. doi:10.7326/0003-4819-128-3-199802010-00001 Figure Legend: Mean changes in body weight (top) and fasting plasma insulin levels (bottom) over 6 years in patients in the primary diet failure group allocated to insulin (squares), sulfonylurea (triangles), or metformin (Xs).Left panels show data from nonobese patients; right panels show data from obese patients. Date of download: 10/20/2017 Copyright © American College of Physicians. All rights reserved.